Epigenetic fragility of the endocannabinoid system under stress: risk for mood disorders and pharmacogenomic implications

References

• 1. Goldstein Ferber S, Trezza V, Weller A. Early life stress and development of the endocannabinoid system: a bidirectional process in programming future coping. Dev. Psychobiol. doi:10.1002/dev.21944 (2019).
  MedlineGoogle Scholar
• 2. Basavarajappa B, Nixon R, Arancio O. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev. Med. Chem. 9(4), 448–462 (2009).
  Medline CASGoogle Scholar
• 3. Monory K, Lutz B. The endocannabinoid system as a therapeutic target in epilepsy. In: Cannabinoids and the Brain. Springer, USA, 407–422 (2008).
  Google Scholar
• 4. Yadid G, Friedman A. Dynamics of the dopaminergic system as a key component to the understanding of depression. Prog. Brain Res. 172, 265–286 (2008).
  Medline CASGoogle Scholar
• 5. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta. Psychiatr. Scand. 124(4), 250–261 (2011).
  Medline CASGoogle Scholar
• 6. Hoehe MR, Caenazzo L, Martinez MM et al. Genetic and physical mapping of the human cannabinoid receptor gene tochromosome 6q14-q15. New Biol!. 3, 880–885 (1991).
  Medline CASGoogle Scholar
• 7. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204, 207–229 (2012).
  Medline CASGoogle Scholar
• 8. Carnevali L, Statello R, Vacondio F et al. Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats. Eur. Neuropsychopharmacol. 32, 77–87 (2020).
  Medline CASGoogle Scholar
• 9. Conradt E, Adkins DE, Crowell SE, Raby KL, Diamond LM, Ellis B. Incorporating epigenetic mechanisms to advance fetal programming theories. Dev. Psychopathol. 30(3), 807–824 (2018).
  MedlineGoogle Scholar
• 10. Wirz L, Reuter M, Felten A, Schwabe L. An endocannabinoid receptor polymorphism modulates affective processing under stress. Soc. Cogn. Affect. Neurosci. 13, 1177–1189 (2018).
  MedlineGoogle Scholar
• 11. Conzelmann A, Reif A, Jacob C et al. A polymorphism in the gene of the endocannabinoid-degrading enzyme FAAH (FAAH C385A) is associated with emotional-motivational reactivity. Psychopharmacology (Berl). 224(4), 573–579 (2012).
  Medline CASGoogle Scholar
• 12. Ruehle S, Rey AA, Remmers F, Lutz B. The endocannabinoid system in anxiety, fear memory and habituation. J. Psychopharmacol. 26(1), 23–39 (2012).
  Medline CASGoogle Scholar
• 13. Lazary J Eszlari N Juhasz G Bagdy G.Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma. Eur. Neuropsychopharmacol. 26(6), 1020–1028 (2016).
  Medline CASGoogle Scholar
• 14. Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 41(1), 80–102 (2016).
  Medline CASGoogle Scholar
• 15. Hill MN, Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol. Mood Anxiety Disord. 3(1), 19 (2013).
  MedlineGoogle Scholar
• 16. Mota N, Sumner JA, Lowe SR et al. The rs1049353 polymorphism in the CNR1 gene interacts with childhood abuse to predict posttraumatic threat symptoms. J. Clin. Psychiatry 76(12), e1622–e1623 (2015).
  MedlineGoogle Scholar
• 17. Doherty TS, Roth TL. Epigenetic landscapes of the adversity-exposed brain. In: Prog. Mol. Biol. Transl. Sci. Elsevier B.V., 1–19 (2018).
  Google Scholar
• 18. Franklin TB, Russig H, Weiss IC et al. Epigenetic transmission of the impact of early stress across generations. Biol. Psychiatry 68(5), 408–415 (2010).
  MedlineGoogle Scholar
• 19. Domschke K, Dannlowski U, Ohrmann P et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur. Neuropsychopharmacol. 18(10), 751–759 (2008).
  Medline CASGoogle Scholar